Melatonin Modified Release Formulations Designed for Sleep Disorders

Vlachou, Marilena; Siamidi, Angeliki

doi:10.5772/intechopen.78337

Cited by 6 publications

(5 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To address this, nanotech ophthalmic systems could be considered to traverse the ocular surface epithelial barrier and reach tissues within the eye globe. Several nanocarriers have been described for ocular drug delivery to different eye segments [ 22 ], and some of them have shown promising results in improving ocular bioavailability, reducing the frequency of administration, and minimizing toxic effects on healthy tissues ( Table 1 ).…”

Section: Topical Formulations Of Melatoninmentioning

confidence: 99%

The Therapeutic Trip of Melatonin Eye Drops: From the Ocular Surface to the Retina

Rusciano,

Russo

2024

Pharmaceuticals

View full text Add to dashboard Cite

Melatonin is a ubiquitous molecule found in living organisms, ranging from bacteria to plants and mammals. It possesses various properties, partly due to its robust antioxidant nature and partly owed to its specific interaction with melatonin receptors present in almost all tissues. Melatonin regulates different physiological functions and contributes to the homeostasis of the entire organism. In the human eye, a small amount of melatonin is also present, produced by cells in the anterior segment and the posterior pole, including the retina. In the eye, melatonin may provide antioxidant protection along with regulating physiological functions of ocular tissues, including intraocular pressure (IOP). Therefore, it is conceivable that the exogenous topical administration of sufficiently high amounts of melatonin to the eye could be beneficial in several instances: for the treatment of eye pathologies like glaucoma, due to the IOP-lowering and neuroprotection effects of melatonin; for the prevention of other dysfunctions, such as dry eye and refractive defects (cataract and myopia) mainly due to its antioxidant properties; for diabetic retinopathy due to its metabolic influence and neuroprotective effects; for macular degeneration due to the antioxidant and neuroprotective properties; and for uveitis, mostly owing to anti-inflammatory and immunomodulatory properties. This paper reviews the scientific evidence supporting the use of melatonin in different ocular districts. Moreover, it provides data suggesting that the topical administration of melatonin as eye drops is a real possibility, utilizing nanotechnological formulations that could improve its solubility and permeation through the eye. This way, its distribution and concentration in different ocular tissues may support its pleiotropic therapeutic effects.

show abstract

Section: Topical Formulations Of Melatoninmentioning

confidence: 99%

The Therapeutic Trip of Melatonin Eye Drops: From the Ocular Surface to the Retina

Rusciano,

Russo

2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…A singlewalled carbon nanotube (SWCN) improved bioabsorption of zaleplon (sedative-hypnotic) via nasal delivery, by increasing carbon nanotube-mediated bloodbrain crossing ability [417], leading to prolonged neuroprotective effect. Melatonin is another suitable therapeutic candidate for insomnia which could be transdermally delivered due to its low molecular weight [415,[418][419][420]. A microneedle patch synthesized from proline, melatonin and silk fibroin has been found effective in maintaining drug concentration in blood and demonstrates physiological resemblance in drug release in Sprague-Dawley rat models of insomnia [416].…”

Section: Biomaterials Stem Cells and Insomniamentioning

confidence: 99%

Clinical Spectrum and Trajectory of Innovative Therapeutic Interventions for Insomnia: A Perspective

Lo¹,

Mishra²,

Lo³

et al. 2022

Aging and disease

View full text Add to dashboard Cite

Increasing incidences of insomnia in adults, as well as the aging population, have been reportedfor their negative impact on the quality of life. Insomnia episodes may be associated with neurocognitive, musculoskeletal, cardiovascular, gastrointestinal, renal, hepatic, and metabolic disorders. Epidemiological evidence also revealed the association of insomnia with oncologic and asthmatic complications, which has been indicated as bidirectional. Two therapeutic approaches including cognitive behavioral therapy (CBT) and drugsbased therapies are being practiced for a long time. However, the adverse events associated with drugs limit their wide and long-term application. Further, Traditional Chinese medicine, acupressure, and pulsed magnetic field therapy may also provide therapeutic relief. Notably, the recently introduced cryotherapy has been demonstrated as a potential candidate for insomnia which could reduce pain, by suppressing oxidative stress and inflammation. It seems that the synergistic therapeutic approach of cryotherapy and the above-mentioned approaches might offer promising prospects to further improve efficacy and safety. Considering these facts, this perspective presents a comprehensive summary of recent advances in pathological aetiologies of insomnia including COVID-19, and its therapeutic management with a greater emphasis on cryotherapy.

show abstract

“…Therefore, the modified release of MLT from oral solid dosage forms that alter the time and/or the rate of MLT release may provide an alternative for MLT delivery and be useful in the treatment of circadian rhythmic disorders, like insomnia, jet lag, seasonal affective disease, shift work syndrome, etc. [6]. The recent advantages of MLT modified-release per oral solid formulations are reviewed below and summarized in Table 1.…”

Section: Advances On the Melatonin Per Os Administered Modified-releamentioning

confidence: 99%

Per Os Administered Modified-Release Solid Formulations of Melatonin: A Review of the Latest Developments Including the Design of Experiments (DoE) Approach

Siamidi¹,

Dotsikas²

2020

Melatonin - The Hormone of Darkness and Its Therapeutic Potential and Perspectives

Self Cite

View full text Add to dashboard Cite

The pineal hormone melatonin (MLT) is a derivative of the amino acid L-tryptophan and controls the circadian diurnal rhythm and the seasonal biorhythm. Exogenous administration is aimed at alleviating sleep-related dysfunctions and jet lag, as it decreases sleep-onset latency, increases total sleep time and improves overall sleep quality. Besides these indications, MLT has been shown to have other actions, such as antioxidant, immune enhancement and anticancer. It has also been shown to be useful against cardiovascular, neurological and psychiatric diseases. In the context of this work, a review of the related literature on the modified release of MLT from its per os administered formulations is presented, including the utilization of the design of experiments (DoE) for the selection of the optimal composition of melatonin formulations. The chapter offers an account of the recent advantages on MLT's solid dosage forms suitable for treating sleep disorders, referring either to its onset or maintenance.

show abstract

Melatonin Modified Release Formulations Designed for Sleep Disorders

Cited by 6 publications

References 50 publications

The Therapeutic Trip of Melatonin Eye Drops: From the Ocular Surface to the Retina

The Therapeutic Trip of Melatonin Eye Drops: From the Ocular Surface to the Retina

Clinical Spectrum and Trajectory of Innovative Therapeutic Interventions for Insomnia: A Perspective

Per Os Administered Modified-Release Solid Formulations of Melatonin: A Review of the Latest Developments Including the Design of Experiments (DoE) Approach

Contact Info

Product

Resources

About